Advanced Renal Cell Carcinoma
Advertisement
Patients underwent treatment with lenvatinib plus everolimus as a second-line therapy.
Dr. Swami investigated the efficacy of cabozantinib in combination with immune checkpoint inhibitors for mccRCC.
Dr. Zakharia continues his commentary on the BTCRC-GU16-043 study investigating guadecitabine and durvalumab in accRCC.
Dr. Zakharia explains why guadecitabine plus durvalumab may be a good treatment approach in patients with advanced RCC.
Drs. Braun and Beckermann stress the importance of adopting an integrative approach to biomarker-based research in RCC.
Drs. Braun and Beckermann review JAVELIN Renal 101, focusing on the impact of avelumab and axitinib treatment on RCC.
Drs. Braun and Beckermann discuss the evolving significance of sarcomatoid histology in guiding treatment decisions for RCC.
Drs. Atkins and Beckermann weigh the potential of targeting Tregs in RCC treatment, particularly in relation to PD-1 therapy.
Drs. Atkins and Beckermann consider biomarkers for patient selection for LAG-3 inhibition and increasing cure rates in RCC.
Drs. Atkins and Beckermann discuss LAG-3 as a novel checkpoint inhibitor combined with anti-PD-1 for kidney cancer.cC
The results of this study are similar to previous data from the phase 3 CONTACT-03 trial.
A randomized, phase 3 trial evaluated the potential of pazopanib versus placebo to improve DFS in patients with mRCC.
Data from the JAVELIN Renal 101, KEYNOTE-426, CheckMate 9ER, CLEAR, and IMmotion151 trials were reviewed.
Dr. George shares his expert opinion on the 8-year CheckMate 214 survival and durable response data in advanced RCC.
Dr. George provides an overview of the adjuvant pembro long-term data and the other adjuvant approaches being investigated.
Researchers analyzed the data from patients who received anti–LAG-3 and anti–PD-1.
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.